AMAG PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1981-01-01

Employees: 440

Market Cap: -

Website: http://www.amagpharma.com

Clinical Trials

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Phase 3

Terminated

Conditions: Iron Deficiency Anemia

Interventions: Drug: Oral Iron
Drug: Ferumoxytol

First Posted Date: 2010-07-01

Last Posted Date: 2022-04-04

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 14

Registration Number: NCT01155375

Locations: 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Completed

Conditions: Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial

Interventions: Drug: ASQ-3, Bayley III, Neurologic exam

First Posted Date: 2010-06-22

Last Posted Date: 2022-05-18

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 245

Registration Number: NCT01146990

Locations: 🇺🇸
Women's Healthcare Associates dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States
🇺🇸
Practice Research Organization, Inc., Dallas, Texas, United States
🇺🇸
Saginaw Valley Medical Research Group, LLC/Women's OB GYN, PC, Saginaw, Michigan, United States

and more 37 locations

A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Iron Sucrose
Drug: Ferumoxytol

First Posted Date: 2010-05-03

Last Posted Date: 2022-04-21

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 605

Registration Number: NCT01114204

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇱🇻
For additional this triinformation regarding investigative sites for al, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riga, Latvia

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferumoxytol

First Posted Date: 2010-05-03

Last Posted Date: 2022-04-21

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 634

Registration Number: NCT01114217

Locations: 🇵🇱
Clinical Trial Site, Wrocław, Poland

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Other: Placebo
Drug: Ferumoxytol

First Posted Date: 2010-04-30

Last Posted Date: 2022-04-21

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 812

Registration Number: NCT01114139

Locations: 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
🇵🇱
Clinical Trial Site, Zgierz, Poland

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

Phase 2

Completed

Conditions: Anemia
Kidney Disease
Iron Deficiency

Interventions: Drug: Ferumoxytol
Drug: Iron Sucrose

First Posted Date: 2010-01-20

Last Posted Date: 2023-07-25

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 162

Registration Number: NCT01052779

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montréal, Quebec, Canada
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

Phase 3

Completed

Conditions: Preterm Birth

Interventions: Drug: Vehicle
Drug: Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL

First Posted Date: 2009-10-29

Last Posted Date: 2022-06-01

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 1740

Registration Number: NCT01004029

Locations: 🇧🇬
Medical Centre "Avicena" Ltd, Sofia, Bulgaria
🇺🇸
Naval Medical Center San Diego - Department of Obstetrics and Gynecology, San Diego, California, United States
🇺🇸
Global OB/GYN Centers, Pembroke Pines, Florida, United States

and more 100 locations

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

Phase 2

Conditions: Peripheral Arterial Disease (PAD)

Interventions: Drug: ferumoxytol

First Posted Date: 2008-07-01

Last Posted Date: 2019-04-26

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 108

Registration Number: NCT00707876

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

Phase 1

Completed

Conditions: Anemia

First Posted Date: 2006-08-04

Last Posted Date: 2022-04-04

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 174

Registration Number: NCT00360425

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Phase 3

Completed

Conditions: Anemia

First Posted Date: 2005-11-21

Last Posted Date: 2015-01-09

Lead Sponsor: AMAG Pharmaceuticals, Inc.

Target Recruit Count: 304

Registration Number: NCT00255424

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy